Evolution d'ontologie : Validation des changements basée sur l'évaluation

National audienceL'évolution d'ontologie est définie comme étant l'adaptation de l'ontologie aux besoins de changements et la propagation de ces changements aux artefacts dépendants tout en préservant la consistance. Par ailleurs, l'évaluation d'ontologie est souvent utilisée pour choisir l'ontologie la plus appropriée en fonction des besoins de l'utilisateur. L'évaluation prend en considération plusieurs aspects de qualité tels que la structure et l'usage. Dans cet article, nous proposons une approche de gestion de l'évolution d'ontologie basée sur la validation de la consistance et l'évaluation de la qualité. La validation de la consistance consiste à vérifier que chaque axiome reste vrai après l'application du changement. L'évaluation de la qualité permet de décider de l'acceptation finale des changements. Un changement qui permet d'améliorer la qualité peut être validé automatiquement sans l'intervention de l'expert

c-Met immunohistochemistry as reflex test at diagnosis for non-small cell lung cancer: a real-world experience from a monocentric case series

International audienceAims Recent clinical trials have shown promising results with drugs targeting the hepatocyte growth factor receptor (c-Met) for advanced non-small cell lung cancers overexpressing c-Met. We assessed reflex testing of c-Met immunohistochemistry (IHC) at diagnosis for NSCLC in the real-world. Methods We retrospectively collected clinical, pathological and molecular data of cases diagnosed with NSCLC in our institution from January 2021 to June 2023. We performed c-Met IHC (SP44 clone) and scored the expression using a H-score and a three-tier classification. Results 391 cases with interpretable c-Met IHC staining were included. The median age at diagnosis was 70 years (range 25–89 years) including 234 males (male/female ratio 1:5). 58% of the samples came from surgical resections, 35% from biopsies and 8% from cytological procedures. 52% of cases were classified as c-Met-positive (H-score≥150) and 19% were classified as c-Met high (≥50%, 3+). 43% of the c-Met neg presented with lymph node and/or visceral metastases at diagnosis vs 55% for c-Met high (p=0.042). 23% of the adenocarcinomas showed c-Met high expression vs 3% for squamous cell carcinomas (p=0.004). 27% of the c-Met neg cases had a high PD-L1 expression vs 58% of c-Met high cases (p<0.001). MET ex14 skipping was present in 8% of the c-Met high cases. Conclusions Systematic c-Met testing in daily routine for NSCLC patients is feasible, highlighting a potential correlation with clinicopathological and molecular features